F-7125

IN THE CLAIMS:

Please amend claim 5 as follows:

bulgi control

5, (Amended) Transdermal therapeutic system according to any one of claims 1-4, wherein the content of the at least one monoterpene ketone in the nicotine-containing matrix is 0.1 to 5.0%-wt.

The amendments to claim 5 are shown by brackets and underscoring in Appendix I.

THE REPORT OF THE PARTY OF THE